The Oncology Institute, Inc.
General ticker "TOI" information:
- Sector: Health Care
- Industry: Medical - Care Facilities
- Capitalization: $3.4B (TTM average)
The Oncology Institute, Inc. follows the US Stock Market performance with the rate: 41.7%.
Estimated limits based on current volatility of 6.8%: low 5.23$, high 5.99$
Factors to consider:
- Total employees count: 825 as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Rapid growth demands resources, Operating losses and profitability, Pandemic risks, Patient recruitment and retention, Third-party risks
- Current price 14.3% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.24$, 4.68$]
- 2026-12-31 to 2027-12-31 estimated range: [0.81$, 3.26$]
Financial Metrics affecting the TOI estimates:
- Positive: with PPE of -6.9 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: 0 < Inventory ratio change, % of 0.73
- Positive: Interest expense per share per price, % of 0.35 <= 0.74
- Positive: Investing cash flow per share per price, % of -0.09 > -0.60
- Negative: Industry operating cash flow per share per price (median), % of 4.90 <= 5.50
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -9.55 <= 19.19
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term TOI quotes
Long-term TOI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $324.24MM | $393.41MM | $502.73MM |
| Operating Expenses | $401.26MM | $453.53MM | $538.81MM |
| Operating Income | $-77.02MM | $-60.12MM | $-36.08MM |
| Non-Operating Income | $-6.09MM | $-4.54MM | $-24.65MM |
| Interest Expense | $6.78MM | $7.50MM | $11.28MM |
| Income(Loss) | $-83.10MM | $-64.66MM | $-60.74MM |
| Taxes | $-0.04MM | $0.00MM | $-0.13MM |
| Net Income(Loss)* | $-83.07MM | $-64.66MM | $-60.61MM |
| Stockholders Equity | $57.02MM | $3.59MM | $-15.72MM |
| Assets | $209.24MM | $172.72MM | $164.66MM |
| Operating Cash Flow | $-36.31MM | $-26.54MM | $-24.59MM |
| Capital expenditure | $4.57MM | $3.79MM | $3.20MM |
| Investing Cash Flow | $62.64MM | $46.21MM | $-3.07MM |
| Financing Cash Flow | $-6.85MM | $-3.49MM | $11.56MM |
| Earnings Per Share** | $-1.13 | $-0.86 | $-0.07 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.